Gurgaon Samachar

Chronic Pain Associated with Painful Diabetic Neuropathy Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Chronic Pain Associated with Painful Diabetic Neuropathy Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

July 05
22:29 2021
Chronic Pain Associated with Painful Diabetic Neuropathy Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Chronic Pain Associated with Painful Diabetic Neuropathy Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Chronic Pain Associated with Painful Diabetic Neuropathy Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Painful Diabetic Neuropathy (PDN) is a well-known complication of diabetes and the most common cause of all neuropathic pain. About one-third of all diabetes patients suffer from PDN. It is defined as the presence of signs and symptoms of nerve dysfunction in patients with diabetes mellitus after the exclusion of other causes.

Patients with painful diabetic neuropathy characteristically present with a tingling sensation, numbness, burning, excruciating stabbing type of pain, sometimes intractable and may be associated with paraesthesia and hyperesthesia coupled with deep aching in feet or hands. Chronic neuropathic pain is present in 13–26% of diabetic patients and can damage peripheral nerves, resulting in severe pain and numbness in the extremities.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/chronic-pain-associated-with-painful-diabetic-neuropathy-market

The Chronic Pain Associated with Painful Diabetic Neuropathy Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Chronic Pain Associated with Painful Diabetic Neuropathy market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Chronic Pain Associated with Painful Diabetic Neuropathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Chronic Pain Associated with Painful Diabetic Neuropathy Market

Chronic Pain Associated with Painful Diabetic Neuropathy Market Key Facts

  • Rassion et al. (2017) conducted a study to collate evidence of painful diabetic neuropathy. It was found that the prevalence varied from 8.2% to 25.7% (US) among all diabetic patients.

  • According to a study conducted by Veves et al. (2008), the epidemiology of PDN has not been well established and based on available data, the prevalence of pain is 10–20% in patients with diabetes and from 40–50% in those with diabetic neuropathy.

  • As per Pesaresi et al. (n.d.)., males develop neuropathy earlier than females, and PDN is more frequent in men than in women.

  • According to a study by Ashley et al. (n.d.), PDN affects around 26% of people with diabetes, resulting in significant physical and social morbidity and impairing quality of life.

  • As per the study conducted by Aaberg et al. (2008), a statistically significant difference was observed in age at onset of diabetic neuropathy between the male and female subjects; this study demonstrated that the males in the study population developed neuropathy earlier than the females.

  • As per Ziegler (2009), chronic neuropathic pain is present in 13–26% of diabetic patients. From a survey in Augsburg, Germany, the prevalence of painful polyneuropathy was found to be 13.3% in diabetic Subjects.

Key Benefits of Chronic Pain Associated with Painful Diabetic Neuropathy Market Report

  • Chronic Pain Associated with Painful Diabetic Neuropathy market report provides an in-depth analysis of Chronic Pain Associated with Painful Diabetic Neuropathy Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Chronic Pain Associated with Painful Diabetic Neuropathy Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Chronic Pain Associated with Painful Diabetic Neuropathy current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Chronic Pain Associated with Painful Diabetic Neuropathy market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Chronic Pain Associated with Painful Diabetic Neuropathy Market

Increased awareness of this unique histology has allowed for the development of specific drugs specific to PDN and has begun to shed light on the similarities and possible unique aspects of PDN. These factors, along with the expected launch of emerging therapies, will boost the Chronic Pain Associated with Painful Diabetic Neuropathy market size growth in the forecast period.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Pain Associated with Painful Diabetic Neuropathy Market Size and Share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Chronic Pain Associated with Painful Diabetic Neuropathy Market Trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology

The epidemiology section covers insights about the historical and current Chronic Pain Associated with Painful Diabetic Neuropathy patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Chronic Pain Associated with Painful Diabetic Neuropathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Pain Associated with Painful Diabetic Neuropathy Market or expected to get launched in the market during the study period. The analysis covers Chronic Pain Associated with Painful Diabetic Neuropathy market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Chronic Pain Associated with Painful Diabetic Neuropathy Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Chronic Pain Associated with Painful Diabetic Neuropathy market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Chronic Pain Associated with Painful Diabetic Neuropathy emerging therapies.

Some of the key players at the global level are developing therapies to treat Chronic Pain Associated with Painful Diabetic Neuropathy (PDN). Several potential therapies are under investigation. These include newer agents, which are undergoing evaluation in chronic pain associated with PDN.

Chronic Pain Associated with Painful Diabetic Neuropathy Companies:

  • NeuroMetrix

  • AstraZeneca 

  • Highland Instruments

  • Nevro Corp

And many others.

Chronic Pain Associated with Painful Diabetic Neuropathy Therapies covered in the report include:

  • HF10 Therapy

  • Active tDCS + Active TUS

  • MEDI7352

  • SENSUS

And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Chronic Pain Associated with Painful Diabetic Neuropathy Competitive Intelligence Analysis

4. Chronic Pain Associated with Painful Diabetic Neuropathy Market Overview at a Glance

5. Chronic Pain Associated with Painful Diabetic Neuropathy Disease Background and Overview

6. Chronic Pain Associated with Painful Diabetic Neuropathy Patient Journey

7. Chronic Pain Associated with Painful Diabetic Neuropathy Epidemiology and Patient Population

8. Chronic Pain Associated with Painful Diabetic Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices

9. Chronic Pain Associated with Painful Diabetic Neuropathy Unmet Needs

10. Key Endpoints of Chronic Pain Associated with Painful Diabetic Neuropathy Treatment

11. Chronic Pain Associated with Painful Diabetic Neuropathy Marketed Products

12. Chronic Pain Associated with Painful Diabetic Neuropathy Emerging Therapies

13. Chronic Pain Associated with Painful Diabetic Neuropathy Seven Major Market Analysis

14. Attribute Analysis

15. Chronic Pain Associated with Painful Diabetic Neuropathy Market Outlook (7 major markets)

16. Chronic Pain Associated with Painful Diabetic Neuropathy Access and Reimbursement Overview

17. KOL Views on the Chronic Pain Associated with Painful Diabetic Neuropathy Market.

18. Chronic Pain Associated with Painful Diabetic Neuropathy Market Drivers

19. Chronic Pain Associated with Painful Diabetic Neuropathy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/chronic-pain-associated-with-painful-diabetic-neuropathy-market

Healthcare Blogs
Neurovascular Thrombectomy Devices in the Pipeline

As per the Delveinsight, in the 7MM, the Neurovascular Thrombectomy Devices market is expected to be dominated by the combinational procedure devices (comprising of SOLONDRA and Solumbra), followed by stent retrievers and lastly, the aspiration catheters, in the year 2026. Some of the key companies in the Neurovascular Thrombectomy Devices market are Edward LifeSciences, Corporation, Stryker, Terumo Europe NV, Boston Scientific Corporation, Medtronic, Acandis GmbH, Perflow Medical, Phenox GmbH, Penumbra, Johnson and Johnson, and several others. For more detailed information, visit: Neurovascular Thrombectomy Devices

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/gurgaon-samachar.com/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share